Pulmonology Medical News about Gemcitabine; Cisplatin; Lung Cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II Clinical Trial
Journal of Thoracic Oncology, 09/03/09

Zwitter M et al. – In the treatment of advanced non–small cell lung cancer, gemcitabine in low dose in prolonged infusion in combination with cisplatin has low toxicity and has activity comparable with gemcitabine in higher dose in standard brief infusion. Low–dose gemcitabine may be preferred for incurable cancer among economically deprivileged patients.

<< Previous
The impact of the lung allocation scoring system at the single...

Next >>
Heart-Lung Transplantation In Situs Inversus Totalis